A "Triple-Acting" Weight-Loss Combination: What Early Data on EloraTZP Show
Every few months lately, I find myself updating the mental list I keep of where obesity pharmacotherapy is heading next, and the data Eli Lilly presented at EASD 2026, the 62nd…
Every few months lately, I find myself updating the mental list I keep of where obesity pharmacotherapy is heading next, and the data Eli Lilly presented at EASD 2026, the 62nd Annual Meeting of the European Association for the Study of Diabetes held in Milan from September 28 to October 2, added a genuinely new entry to that list: a combination product the company is calling eloraTZP.
EloraTZP pairs two mechanisms that work through different pathways. The first component, eloralintide, is a once-weekly, selective amylin receptor agonist. Amylin is a hormone made in the pancreas alongside insulin, and drugs that mimic it work primarily by slowing gastric emptying and increasing satiety signals to the brain, which is a distinct mechanism from incretin-based drugs. The second component is tirzepatide, the dual GIP/GLP-1 receptor agonist already familiar to patients as Mounjaro and Zepbound. Combining an amylin agonist with an incretin-based agent is meant to attack appetite regulation from two separate angles simultaneously, which is why Lilly describes it as a "triple-acting" approach, counting GIP, GLP-1, and amylin receptor activity together.
The headline number comes from a Phase 1 study: adding eloralintide 3 mg to tirzepatide 5 mg produced 17 percent total body weight loss over just 16 weeks, compared with 10 percent for tirzepatide 5 mg alone over the same period. That is a substantial relative increase in a fairly short window, achieved by adding a second mechanism onto a starting, rather than maximal, tirzepatide dose. Phase 2 data, also unveiled at an EASD symposium, extend this work into adults with obesity or overweight who also have type 2 diabetes, a population where weight loss and glycemic control both matter and often move together.
I want to be precise about what this data can and cannot tell us yet. This is still early-phase work: a 16-week Phase 1 readout and a Phase 2 program that is only beginning to be presented, not a completed Phase 3 trial with the kind of multi-year safety and durability data we now have for tirzepatide itself. We do not yet know the optimal maintenance dose, the long-term tolerability profile of combining these two mechanisms, or how weight loss and body composition (particularly preservation of lean mass) compare with tirzepatide at its own higher, maximally effective doses rather than a low 5 mg starting dose. Comparing eloraTZP against a submaximal tirzepatide dose, rather than against the highest approved dose, is a meaningful limitation when interpreting how large this benefit truly is in practice.
That caveat aside, the underlying biological logic is sound and, to me, genuinely exciting. We have reached a point in obesity medicine where single-mechanism drugs, even highly effective ones like tirzepatide, appear to have a ceiling of effect for a meaningful subset of patients. Layering a distinct hormonal pathway like amylin onto an existing incretin backbone is one of the more promising strategies for pushing average weight loss results further, potentially approaching outcomes we have historically only associated with bariatric surgery, without requiring an operation. Lilly is pursuing a similar logic with other programs in its pipeline, and I expect multiple pharmaceutical companies to pursue amylin-incretin combinations over the next several years.
For my patients who ask whether something even more effective than their current medication is coming, my honest answer continues to be yes, something usually is, but it typically takes several more years of Phase 2 and Phase 3 trials before it reaches a pharmacy shelf with a full safety record behind it. EloraTZP is a drug I will be watching closely as it moves through that pipeline, but not yet one I can offer any patient outside of a clinical trial.
Source: Eli Lilly and Company, data presented at EASD 2026 (62nd Annual Meeting of the European Association for the Study of Diabetes, Milan, September 28–October 2, 2026); Phase 1 eloralintide plus tirzepatide combination data and Phase 2 program in adults with obesity/overweight and type 2 diabetes.
Related articles
How Do I Use Mounjaro? A Patient's Guide to Dosing, Injections, and Safety
Learn how to correctly use Mounjaro (tirzepatide), including injection sites, the step-up dosing schedule, handling missed doses, and storage guidelines.
Can GLP-1 Drugs Ease the Strain on a Failing Heart? New Pressure-Monitor Data Say Possibly Yes
Can GLP 1 Drugs Ease the Strain on a Failing Heart? New Pressure Monitor Data Say Possibly Yes Most of what we know about GLP 1 and dual GLP 1/GIP medications in heart failure…
A Once-Monthly Weight-Loss Injection? What MariTide's Phase 2 Data Actually Show
One of the most common frustrations I hear from patients on weekly injectable weight loss medications is not about effectiveness — most patients are genuinely pleased with their…
Have questions about your own health?
Ask the AI Knowledge Center — trained on Professor Jamal's own publications and guidelines — or book a consultation in person.